Kiniksa Pharmaceuticals (KNSA) Stock Forecast, Price Target & Predictions
KNSA Stock Forecast
Kiniksa Pharmaceuticals stock forecast is as follows: an average price target of $36.33 (represents a 72.26% upside from KNSA’s last price of $21.09) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
KNSA Price Target
The average price target for Kiniksa Pharmaceuticals (KNSA) is $36.33 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $34.00. This represents a potential 72.26% upside from KNSA's last price of $21.09.
KNSA Analyst Ratings
According to 3 Wall Street analysts, Kiniksa Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for KNSA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Kiniksa Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 29, 2024 | Liisa Bayko | Evercore ISI | $35.00 | $23.27 | 50.44% | 65.96% |
| Sep 13, 2024 | Roger Song | Jefferies | $40.00 | $24.49 | 63.33% | 89.66% |
| May 03, 2024 | Eva Fortea Verdejo | Wells Fargo | $34.00 | $19.38 | 75.44% | 61.21% |
The latest Kiniksa Pharmaceuticals stock forecast, released on Oct 29, 2024 by Liisa Bayko from Evercore ISI, set a price target of $35.00, which represents a 50.44% increase from the stock price at the time of the forecast ($23.27), and a 65.96% increase from KNSA last price ($21.09).
Kiniksa Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 3 |
| Avg Price Target | $35.00 | $37.50 | $36.33 |
| Last Closing Price | $21.09 | $21.09 | $21.09 |
| Upside/Downside | 65.96% | 77.81% | 72.26% |
In the current month, the average price target of Kiniksa Pharmaceuticals stock is $35.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 65.96% increase as opposed to Kiniksa Pharmaceuticals's last price of $21.09. This month's average price target is down -6.67% compared to last quarter, and down -3.66% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 29, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Sep 13, 2024 | Jefferies | - | Buy | Initialise |
| Jul 24, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 03, 2024 | Wells Fargo | - | Overweight | Initialise |
Kiniksa Pharmaceuticals's last stock rating was published by Evercore ISI on Oct 29, 2024. The company gave KNSA a "Outperform" rating, the same as its previous rate.
Kiniksa Pharmaceuticals Financial Forecast
Kiniksa Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $67.05M | $71.47M | $48.34M | $61.88M | $99.14M | $26.97M | $32.19M | $18.75M | $12.10M | $7.70M | - |
| Avg Forecast | $155.40M | $151.80M | $140.75M | $138.41M | $123.28M | $111.51M | $90.60M | $76.97M | $73.25M | $64.55M | $52.06M | $46.61M | $45.12M | $93.58M | $28.42M | $30.10M | $17.60M | $10.26M | $4.29M | $7.78M |
| High Forecast | $161.03M | $157.30M | $145.85M | $139.84M | $123.75M | $115.55M | $90.85M | $76.97M | $74.13M | $64.55M | $53.95M | $48.30M | $46.75M | $93.58M | $28.42M | $30.10M | $17.60M | $10.26M | $4.29M | $7.78M |
| Low Forecast | $150.92M | $147.43M | $136.69M | $136.97M | $123.03M | $108.29M | $90.35M | $76.97M | $72.38M | $64.55M | $50.56M | $45.26M | $43.82M | $93.58M | $28.42M | $30.10M | $17.60M | $10.26M | $4.29M | $7.78M |
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.04% | 1.37% | 1.04% | 1.37% | 1.06% | 0.95% | 1.07% | 1.07% | 1.18% | 1.80% | - |
Kiniksa Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $73.25M, with a low forecast of $72.38M, and a high forecast of $74.13M. KNSA's average Quarter revenue forecast represents a 9.26% increase compared to the company's last Quarter revenue of $67.05M (Sep 23).
Kiniksa Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-10.93M | $-3.15M | $-11.20M | $6.05M | $46.41M | $-19.37M | $-23.32M | $-35.39M | $-30.00M | $-39.83M | $-48.96M |
| Avg Forecast | $29.83M | $29.14M | $27.02M | $26.57M | $23.66M | $21.41M | $17.39M | $-22.20M | $14.06M | $12.39M | $9.99M | $-23.74M | $-24.42M | $17.95M | $5.45M | $-25.39M | $3.38M | $1.97M | $823.11K | $-48.97M |
| High Forecast | $30.91M | $30.20M | $28.00M | $26.84M | $23.76M | $22.18M | $17.44M | $-17.76M | $14.23M | $12.39M | $10.36M | $-18.99M | $-19.54M | $17.95M | $5.45M | $-20.31M | $3.38M | $1.97M | $823.11K | $-39.18M |
| Low Forecast | $28.97M | $28.30M | $26.24M | $26.29M | $23.62M | $20.79M | $17.34M | $-26.63M | $13.90M | $12.39M | $9.71M | $-28.49M | $-29.30M | $17.95M | $5.45M | $-30.47M | $3.38M | $1.97M | $823.11K | $-58.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.88% | -0.32% | 0.47% | -0.25% | 2.59% | -3.55% | 0.92% | -10.48% | -15.25% | -48.39% | 1.00% |
1 analysts predict KNSA's average Quarter EBITDA for Mar 23 to be $-23.74M, with a high of $-18.99M and a low of $-28.49M. This is -492.56% lower than Kiniksa Pharmaceuticals's previous annual EBITDA (Dec 22) of $6.05M.
Kiniksa Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | $-13.86M | $14.97M | $-12.27M | $4.46M | $224.09M | $-19.98M | $-25.21M | $-36.33M | $-30.54M | $-41.56M | $-49.48M |
| Avg Forecast | $13.27M | $10.04M | $5.98M | $6.22M | $2.30M | $1.67M | $-5.51M | $-24.73M | $-7.06M | $-11.89M | $-10.16M | $-26.45M | $-25.07M | $33.65M | $-32.31M | $-28.28M | $-29.09M | $-45.93M | $-60.12M | $-49.48M |
| High Forecast | $13.89M | $10.51M | $6.26M | $26.42M | $4.27M | $1.75M | $-5.31M | $-19.78M | $-2.57M | $-11.45M | $-9.78M | $-21.16M | $-20.06M | $33.65M | $-32.31M | $-22.63M | $-29.09M | $-45.93M | $-60.12M | $-39.59M |
| Low Forecast | $12.77M | $9.67M | $5.75M | $-13.99M | $-1.97M | $1.61M | $-5.77M | $-29.67M | $-11.55M | $-12.45M | $-10.64M | $-31.74M | $-30.09M | $33.65M | $-32.31M | $-33.94M | $-29.09M | $-45.93M | $-60.12M | $-59.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.17% | -1.47% | 0.46% | -0.18% | 6.66% | 0.62% | 0.89% | 1.25% | 0.67% | 0.69% | 1.00% |
Kiniksa Pharmaceuticals's average Quarter net income forecast for Sep 23 is $-11.89M, with a range of $-12.45M to $-11.45M. KNSA's average Quarter net income forecast represents a -179.43% decrease compared to the company's last Quarter net income of $14.97M (Jun 23).
Kiniksa Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | $34.47M | $29.18M | $29.05M | $27.21M | $24.68M | $23.84M | $22.22M | $22.74M | $20.76M | $21.85M | $20.60M |
| Avg Forecast | $160.17M | $156.47M | $145.07M | $142.66M | $127.06M | $114.94M | $93.38M | $21.79M | $75.51M | $66.54M | $53.66M | $23.31M | $15.69M | $96.45M | $29.29M | $24.93M | $18.14M | $10.57M | $4.42M | $8.01M |
| High Forecast | $165.98M | $162.14M | $150.33M | $144.14M | $127.56M | $119.10M | $93.65M | $26.15M | $76.40M | $66.54M | $55.61M | $27.97M | $18.83M | $96.45M | $29.29M | $29.91M | $18.14M | $10.57M | $4.42M | $8.01M |
| Low Forecast | $155.55M | $151.96M | $140.89M | $141.18M | $126.81M | $111.62M | $93.12M | $17.43M | $74.61M | $66.54M | $52.11M | $18.65M | $12.56M | $96.45M | $29.29M | $19.94M | $18.14M | $10.57M | $4.42M | $8.01M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.52% | 0.54% | 1.25% | 1.73% | 0.26% | 0.81% | 0.89% | 1.25% | 1.96% | 4.94% | 2.57% |
Kiniksa Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $75.51M, based on 3 Wall Street analysts, with a range of $74.61M to $76.40M. The forecast indicates a 119.06% rise compared to KNSA last annual SG&A of $34.47M (Sep 23).
Kiniksa Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.20 | $0.21 | $-0.18 | $0.06 | $3.23 | $-0.29 | $-0.36 | $-0.53 | $-0.44 | $-0.61 | $-0.72 |
| Avg Forecast | $0.18 | $0.14 | $0.08 | $0.09 | $0.03 | $0.02 | $-0.08 | $-0.08 | $-0.10 | $-0.17 | $-0.14 | $-0.16 | $-0.20 | $0.47 | $-0.46 | $-0.43 | $-0.41 | $-0.65 | $-0.85 | $-0.72 |
| High Forecast | $0.19 | $0.15 | $0.09 | $0.37 | $0.06 | $0.02 | $-0.07 | $-0.08 | $-0.04 | $-0.16 | $-0.14 | $-0.15 | $-0.19 | $0.47 | $-0.46 | $-0.43 | $-0.41 | $-0.65 | $-0.85 | $-0.72 |
| Low Forecast | $0.18 | $0.13 | $0.08 | $-0.20 | $-0.03 | $0.02 | $-0.08 | $-0.09 | $-0.16 | $-0.17 | $-0.15 | $-0.17 | $-0.21 | $0.47 | $-0.46 | $-0.43 | $-0.41 | $-0.65 | $-0.85 | $-0.72 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.21% | -1.48% | 1.13% | -0.30% | 6.82% | 0.64% | 0.84% | 1.29% | 0.68% | 0.72% | 0.99% |
According to 1 Wall Street analysts, Kiniksa Pharmaceuticals's projected average Quarter EPS for Sep 23 is $-0.17, with a low estimate of $-0.17 and a high estimate of $-0.16. This represents a -178.95% decrease compared to KNSA previous annual EPS of $0.21 (Jun 23).
Kiniksa Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $1.73 | $33.86 | 1857.23% | Buy |
| SPRO | Spero Therapeutics | $1.19 | $10.00 | 740.34% | Buy |
| CHRS | Coherus BioSciences | $1.10 | $9.00 | 718.18% | Hold |
| GOSS | Gossamer Bio | $0.66 | $3.75 | 468.18% | Buy |
| LRMR | Larimar Therapeutics | $6.13 | $20.33 | 231.65% | Buy |
| GPCR | Structure Therapeutics | $30.10 | $92.40 | 206.98% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| PHAT | Phathom Pharmaceuticals | $9.45 | $25.83 | 173.33% | Buy |
| KURA | Kura Oncology | $10.06 | $26.00 | 158.45% | Buy |
| CGEM | Cullinan Oncology | $12.22 | $31.50 | 157.77% | Buy |
| REPL | Replimune Group | $11.05 | $24.20 | 119.00% | Buy |
| COGT | Cogent Biosciences | $8.98 | $18.83 | 109.69% | Buy |
| KRON | Kronos Bio | $0.87 | $1.63 | 87.36% | Buy |
| BOLT | Bolt Biotherapeutics | $0.57 | $1.00 | 75.44% | Hold |
| KNSA | Kiniksa Pharmaceuticals | $21.09 | $36.33 | 72.26% | Buy |
| NUVL | Nuvalent | $92.73 | $111.57 | 20.32% | Buy |
| ACLX | Arcellx | $87.22 | $83.00 | -4.84% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |